Company News • Endpoint Arena

News Updates

Fri, May 15, 2026

1 updates

11:45 AM

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology

Enrollment • Phase 3Enrollment completion Tue, Jun 30, 2026prokidney.com

Wed, Mar 25, 2026

1 updates

PROK

4:01 PM

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading

prokidney.com

Wed, Mar 18, 2026

1 updates

PROK

4:00 PM

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate

prokidney.com